Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for LLY
74.99
+0.91 (1.23%)
After Hours: 73.70 -1.29 (-1.72%)
May 24, 5:27PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 74.36 - 75.20
52 week 67.88 - 92.85
Open 74.55
Vol / Avg. 3.71M/3.92M
Mkt cap 82.02B
P/E 34.42
Div/yield 0.51/2.72
EPS 2.18
Shares 1.10B
Beta 0.19
Inst. own 76%
Jul 26, 2016
Q2 2016 Eli Lilly and Co Earnings Release - 9:30AM EDT - Add to calendar
Jul 26, 2016
Q2 2016 Eli Lilly and Co Earnings Call - 9:00AM EDT - Add to calendar
Jun 8, 2016
Eli Lilly and Co at Goldman Sachs Global Healthcare Conference - 1:40PM EDT - Add to calendar
Jun 2, 2016
Eli Lilly and Co at Sanford C Bernstein Strategic Decisions Conference - 11:00AM EDT - Add to calendar
May 24, 2016
Eli Lilly and Co Investment Community R&D Update Meeting (Session 2)
May 24, 2016
Eli Lilly and Co Investment Community R&D Update Meeting (Session 1)
May 11, 2016
Eli Lilly and Co at Bank of America Merrill Lynch Health Care Conference - Webcast
May 3, 2016
Eli Lilly and Co Annual Shareholders Meeting (Estimated)
May 2, 2016
Eli Lilly and Co Annual Shareholders Meeting
Apr 26, 2016
Q1 2016 Eli Lilly and Co Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 9.05% 12.07%
Operating margin 14.71% 12.64%
EBITD margin - 25.15%
Return on average assets 5.02% 6.70%
Return on average equity 11.93% 16.09%
Employees 41,275 -
CDP Score - 89 C

Address

Lilly Corporate Ctr, Drop Code 1112
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company's animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 51
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 56
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 62
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 47
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 53
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 50
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 49
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 51
Bio & Compensation  - Reuters
Barton R. Peterson Senior Vice President - Corporate Affairs and Communications
Age: 57
Bio & Compensation  - Reuters